Literature DB >> 23641690

Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.

Dhaval K Shah, Frank Barletta, Alison Betts, Steven Hansel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23641690     DOI： 10.4155/bio.13.78

Source DB:  PubMed          Journal:  Bioanalysis        ISSN： 1757-6180            Impact factor:   2.681


× No keyword cloud information.
  8 in total

1.  Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.

Authors:  M Benjamin Hock; Karen E Thudium; Montserrat Carrasco-Triguero; Nikolai F Schwabe
Journal:  AAPS J       Date:  2014-11-08       Impact factor: 4.009

Review 2.  Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.

Authors:  Aman P Singh; Young G Shin; Dhaval K Shah
Journal:  Pharm Res       Date:  2015-02-11       Impact factor: 4.200

3.  A priori prediction of tumor payload concentrations: preclinical case study with an auristatin-based anti-5T4 antibody-drug conjugate.

Authors:  Dhaval K Shah; Lindsay E King; Xiaogang Han; Jo-Ann Wentland; Yanhua Zhang; Judy Lucas; Nahor Haddish-Berhane; Alison Betts; Mauricio Leal
Journal:  AAPS J       Date:  2014-03-01       Impact factor: 4.009

4.  Measurement and Mathematical Characterization of Cell-Level Pharmacokinetics of Antibody-Drug Conjugates: A Case Study with Trastuzumab-vc-MMAE.

Authors:  Aman P Singh; Dhaval K Shah
Journal:  Drug Metab Dispos       Date:  2017-08-18       Impact factor: 3.922

5.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin.

Authors:  Alison M Betts; Nahor Haddish-Berhane; John Tolsma; Paul Jasper; Lindsay E King; Yongliang Sun; Subramanyam Chakrapani; Boris Shor; Joseph Boni; Theodore R Johnson
Journal:  AAPS J       Date:  2016-05-19       Impact factor: 4.009

6.  Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.

Authors:  Hsuan-Ping Chang; Zhe Li; Dhaval K Shah
Journal:  Pharm Res       Date:  2022-01-19       Impact factor: 4.200

7.  Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice.

Authors:  Sanne Terryn; Aurélie Francart; Sophie Lamoral; Anna Hultberg; Heidi Rommelaere; Angela Wittelsberger; Filip Callewaert; Thomas Stohr; Kris Meerschaert; Ingrid Ottevaere; Catelijne Stortelers; Peter Vanlandschoot; Michael Kalai; Steven Van Gucht
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

8.  World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

Authors:  Christine Klinguer-Hamour; Pavel Strop; Dhaval K Shah; Laurent Ducry; April Xu; Alain Beck
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.